Apellis Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	781.37	396.59	75.42	66.56	250.65	Upgrade
Revenue Growth (YoY)	97.02%	425.83%	13.31%	-73.44%	-	Upgrade
Cost of Revenue	445.29	412.9	392.87	426.07	25.05	Upgrade
Gross Profit	336.07	-16.31	-317.45	-359.51	225.6	Upgrade
Selling, General & Admin	501.05	500.82	277.16	176.77	139.4	Upgrade
Research & Development	-	-	-	-	299.92	Upgrade
Operating Expenses	501.05	500.82	277.16	176.77	439.32	Upgrade
Operating Income	-164.98	-517.12	-594.61	-536.28	-213.73	Upgrade
Interest Expense	-40.39	-29.58	-32.63	-13.24	-29.94	Upgrade
Interest & Investment Income	12.77	20.93	8.91	0.42	4.16	Upgrade
Other Non Operating Income (Expenses)	-2.17	-0.73	-0.29	-96.31	-103.53	Upgrade
EBT Excluding Unusual Items	-194.77	-526.5	-618.61	-645.41	-343.03	Upgrade
Other Unusual Items	-1.95	-	-32.89	-100.59	-	Upgrade
Pretax Income	-196.72	-526.5	-651.5	-746	-343.03	Upgrade
Income Tax Expense	1.16	2.13	0.67	0.35	1.85	Upgrade
Net Income	-197.88	-528.63	-652.17	-746.35	-344.87	Upgrade
Net Income to Common	-197.88	-528.63	-652.17	-746.35	-344.87	Upgrade
Shares Outstanding (Basic)	124	119	106	84	75	Upgrade
Shares Outstanding (Diluted)	124	119	106	84	75	Upgrade
Shares Change (YoY)	4.40%	11.84%	25.70%	12.32%	20.79%	Upgrade
EPS (Basic)	-1.60	-4.45	-6.15	-8.84	-4.59	Upgrade
EPS (Diluted)	-1.60	-4.45	-6.15	-8.84	-4.59	Upgrade
Free Cash Flow	-88.27	-595.51	-515.27	-564.23	-165.91	Upgrade
Free Cash Flow Per Share	-0.71	-5.02	-4.86	-6.68	-2.21	Upgrade
Gross Margin	43.01%	-4.11%	-	-	90.01%	Upgrade
Operating Margin	-21.11%	-130.39%	-788.38%	-805.67%	-85.27%	Upgrade
Profit Margin	-25.32%	-133.29%	-864.70%	-1121.28%	-137.59%	Upgrade
Free Cash Flow Margin	-11.30%	-150.16%	-683.18%	-847.66%	-66.19%	Upgrade
EBITDA	-163.18	-515.34	-593.06	-534.9	-213.09	Upgrade
EBITDA Margin	-20.88%	-129.94%	-	-	-85.02%	Upgrade
D&A For EBITDA	1.8	1.78	1.55	1.38	0.64	Upgrade
EBIT	-164.98	-517.12	-594.61	-536.28	-213.73	Upgrade
EBIT Margin	-21.11%	-130.39%	-	-	-85.27%	Upgrade
Revenue as Reported	781.37	396.59	75.42	66.56	250.65	Upgrade

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q